Markets
Enanta Stock Plunges 14% After Wider Loss And Eczema Drug-Testing Delay
The royalty-funded drug developer also faces a leadership change, with its chief executive planning to retire by February 2027.
Enanta Pharmaceuticals (ENTA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The royalty-funded drug developer also faces a leadership change, with its chief executive planning to retire by February 2027.
SEC Filings
The adviser and its sole manager reported the same shares, while Enanta expects its cash to fund operations into fiscal 2029.
Earnings
A manufacturing delay pushed the eczema-drug testing application to the second quarter of 2027.
SEC Filings
The Unified Patent Court ruled the '265 patent invalid, ending Enanta's infringement case covering 18 EU member states.
Markets
The drug developer created a chief operating officer post and is searching for a successor to its longtime chief executive.
SEC Filings
Tara Kieffer becomes Enanta's first-ever Chief Operating Officer while the board searches inside and outside for a CEO successor.
SEC Filings
The position in the Watertown drug developer is held for ordinary business, not to influence control, BlackRock certified.